Literature DB >> 3815724

The enterohepatic circulation of methotrexate in vivo: inhibition by bile salt.

D Griffin, H M Said.   

Abstract

We examined the enterohepatic circulation of methotrexate (MTX) in the rat in vivo and determined the effect of the unconjugated bile salt, cholate, on the process. MTX (70 mg/kg body weight) was administered i. v. and the bile salt (1 mM) was delivered through intestinal perfusion. In the control group 38.43% +/- 4% of the administered dose of MTX appeared in bile 2 h after administration of the drug. In the bile salt-treated group 21.4% +/- 3.7% of the administered doses of MTX appeared in bile, which was significantly lower (P less than 0.01) than the proportion in the control group. The liver content of MTX was depressed by 23% in the bile salt-treated group compared with the control group. This study demonstrates, in vivo, the important role that the enterohepatic circulation plays in exposing the small intestine to toxic levels of MTX and shows that the unconjugated bile salt, cholate, inhibits the process.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3815724     DOI: 10.1007/bf00296253

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  Hepatic uptake, intracellular protein binding and biliary excretion of amethopterin.

Authors:  W B Strum; H H Liem
Journal:  Biochem Pharmacol       Date:  1977-07-01       Impact factor: 5.858

Review 2.  The enterohepatic circulation of bile acids in man.

Authors:  A F Hofmann
Journal:  Clin Gastroenterol       Date:  1977-01

Review 3.  Clinical pharmacokinetics of methotrexate.

Authors:  D D Shen; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

Review 4.  The pharmacology and clinical use of methotrexate.

Authors:  J Jolivet; K H Cowan; G A Curt; N J Clendeninn; B A Chabner
Journal:  N Engl J Med       Date:  1983-11-03       Impact factor: 91.245

5.  Absorption of 5-methyltetrahydrofolate in rat jejunum with intact blood and lymphatic vessels.

Authors:  H M Said; D Hollander; D Katz
Journal:  Biochim Biophys Acta       Date:  1984-09-05

Review 6.  The clinical pharmacology of methotrexate: new applications of an old drug.

Authors:  W A Bleyer
Journal:  Cancer       Date:  1978-01       Impact factor: 6.860

7.  Inhibitory effect of bile salts on the enterohepatic circulation of methotrexate in the unanesthetized rat: inhibition of methotrexate intestinal absorption.

Authors:  H M Said; D Hollander
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Inhibitory effect of unconjugated bile acids on the enterohepatic circulation of methotrexate.

Authors:  H M Said; W B Strum; D Hollander
Journal:  J Pharmacol Exp Ther       Date:  1984-12       Impact factor: 4.030

9.  Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. A double-blind controlled study.

Authors:  H Fromm; J W Roat; V Gonzalez; R P Sarva; S Farivar
Journal:  Gastroenterology       Date:  1983-12       Impact factor: 22.682

Review 10.  Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety.

Authors:  L J Schoenfield; J M Lachin
Journal:  Ann Intern Med       Date:  1981-09       Impact factor: 25.391

  10 in total
  4 in total

1.  Involvement of multidrug resistance-associated protein 1 in intestinal toxicity of methotrexate.

Authors:  Sayaka Kato; Katsuaki Ito; Yukio Kato; Tomohiko Wakayama; Yoshiyuki Kubo; Shoichi Iseki; Akira Tsuji
Journal:  Pharm Res       Date:  2009-03-14       Impact factor: 4.200

2.  Pharmacokinetic studies with the antifolate C2-desamino-C2-methyl-N10-propargyl-2'-trifluoromethyl-5,8-dideazafolic acid (CB3988) in mice and rats using in vivo 19F-NMR spectroscopy.

Authors:  D R Newell; R J Maxwell; G M Bisset; D I Jodrell; J R Griffiths
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

Review 3.  Pharmacomicrobiology of Methotrexate in Rheumatoid Arthritis: Gut Microbiome as Predictor of Therapeutic Response.

Authors:  Huanhuan Yan; Rui Su; Hongwei Xue; Chong Gao; Xiaofeng Li; Caihong Wang
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

Review 4.  Molecular mechanism of action and pharmacokinetic properties of methotrexate.

Authors:  V Maksimovic; Z Pavlovic-Popovic; S Vukmirovic; J Cvejic; A Mooranian; H Al-Salami; M Mikov; S Golocorbin-Kon
Journal:  Mol Biol Rep       Date:  2020-05-15       Impact factor: 2.316

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.